简体
  • 简体中文
  • 繁体中文
×

热门资讯> 正文

淀粉制药(纳斯达克：AMLX)股价在分析师上调后出现缺口

2022-07-07 13:21

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) gapped up prior to trading on Wednesday after Citigroup raised their price target on the stock from $33.00 to $37.00. The stock had previously closed at $19.50, but opened at $20.14. Citigroup currently has a buy rating on the stock. Amylyx Pharmaceuticals shares last traded at $21.16, with a volume of 6,981 shares trading hands.

在花旗集团将Amylyx制药公司(纳斯达克代码：AMLX-GET评级)的目标价从33.00美元上调至37.00美元后，该公司股价周三盘前大幅上涨。该股此前收于19.50美元，但开盘报20.14美元。花旗集团目前对该股的评级为买入。Amylyx PharmPharmticals的股票最新报21.16美元，成交量为6981股。

The firm's fifty day moving average price is $12.59.

该公司的50日移动均线价格为12.59美元。

Get
到达
Amylyx Pharmaceuticals
Amylyx制药公司
alerts:
警报：

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.18). On average, equities research analysts predict that Amylyx Pharmaceuticals, Inc. will post -3.3 EPS for the current year.

淀粉制药(纳斯达克：AMLX-GET评级)最近一次发布季度收益数据是在5月12日(星期四)。该公司公布本季度每股收益(0.93美元)，低于普遍预期的(0.75美元)和(0.18美元)。股票研究分析师平均预测，Amylyx制药公司本年度每股收益将为3.3%。

Amylyx Pharmaceuticals Company Profile
Amylyx制药公司简介
(NASDAQ:AMLX)
(纳斯达克：AMLX)

Amylyx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.

Amylyx制药公司是一家临床阶段的生物制药公司，致力于开发各种治疗肌萎缩侧索硬化症(ALS)和其他神经退行性疾病的药物。该公司的产品线包括AMX0035，这是一种由苯丁酸钠和牛磺酸二醇组成的双重UPR-Bax细胞凋亡抑制剂，用于治疗肌萎缩侧索硬化症。

Read More

阅读更多内容

  • Get a free copy of the StockNews.com research report on Amylyx Pharmaceuticals (AMLX)
  • Recession Resistant Grocery Outlet Holding Corp Quietly Sets New High
  • It's Not Too Late For These Undervalued Energy Stocks
  • Three Cheap Stocks That Just Got Upgraded
  • 3 Home Improvement Stocks That Can Renovate Your Portfolio
  • Looking to Dump These 3 Possible Delisted Chinese Stocks? Let's Take a Look.
  • 免费获取StockNews.com关于Amylyx制药(AMLX)的研究报告
  • 抗衰退杂货直销控股公司悄悄创新高
  • 对这些被低估的能源类股来说，现在还不算太晚
  • 刚刚升级的三只便宜的股票
  • 3只家装类股，可以重塑你的投资组合
  • 想抛售这3只可能退市的中国股票吗？让我们来看看。

Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接受Amylyx制药日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Amylyx制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
问答大全
（工作日09：30 - 次日05：30）
客户端：
关注我们：
  • 微信公众号二维码

© 2025 深圳市时代华盛网络科技有限公司版权所有 粤ICP备16068286号